Tucked into another incredibly busy news week was Eli Lilly’s announcement that their weight loss pill, Orforglipron, passed a key weight loss trial. Earlier, there was concern that a large percentage of participants who took the daily pill during a trial stopped, and the overall average percent of weight loss of 12.4% over 18 months was not impressive enough. What’s certain at Lilly, the maker of some of the world’s best-selling injectable weight loss drugs, including Mounjaro and Zepbound, is that they will immediately fast-track approval for the new obesity pill and give it a brand name on which to market. What’s less certain is when the product will be approved and available. Some are saying early 2026 is a possibility in the US. For folks who avoid injectables, a daily pill priced lower than the existing GLP-1 products may be just what the doctor ordered to begin a healthier lifestyle. Don’t wait for the new year to make healthy improvements in your marketing outreach. Redi-Data gives you access to high-quality healthcare professional data, including MDs, DOs, NPs, and PAs. Connect with qualified healthcare professionals (HCPs) and target specific demographics and specialties. Leverage prescription (Rx) habits that align with your goals, including high writers of GLP-1 injectables for weight loss such as Mounjaro, Zepbound, Saxenda, Wegovy, and Ozempic. Layer NPI numbers, ICD-10 codes, or CPT codes to fine-tune your targeting to granular and specific variables. Expand your reach with programmatic advertising and reach your target audience with a curated custom segment. Enhance outreach precision with powerful, multichannel capabilities to connect your unique message with the right audience at the right time, maximizing ad spend ROI. To learn more, contact a Red-Data sales rep today. Better Data, Better Outcomes.